{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:08Z","timestamp":1791489548135,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated the real-world tolerability and effectiveness of tocilizumab in Japanese patients with Takayasu arteritis (TAK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with TAK who had not received tocilizumab in the previous 6\u2009months were enrolled in ACTEMRA\u00ae (ACT)-Bridge, a phase 4, observational study, from 66 Japanese institutions (enrolment period, September 2017 to September 2020) and received weekly subcutaneous tocilizumab 162\u2009mg (observation period, 52\u2009weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 120 patients included (mean age, 38.4\u2009years; mean disease duration, 7.7\u2009years; treated for relapse, 50.8%; previous immunosuppressant use, 57.5%; glucocorticoid use at baseline, 97.5%), 49 (40.8%) reported adverse events. The most common adverse event of special interest was serious infection (7.5%). Relapse was observed in 24 (20.0%) patients (0.8%, 2.5%, and 16.7% reporting \u22653, 2, and 1 relapses, respectively). The reasons for diagnosing relapse included chest and back pain (45.8%), neck pain (25.0%), fatigue (16.7%), fever and headache (12.5% each), abnormal imaging findings (50.0%), and elevated inflammatory markers (16.7%). At the last observation, 83.0% of relapse-free patients recorded a concomitant glucocorticoid dose (prednisolone equivalent) &amp;lt;10\u2009mg\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated the effectiveness of tocilizumab in patients with TAK, with no new safety concerns. Tocilizumab plus glucocorticoids may be considered a treatment option for TAK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roac099","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T11:18:24Z","timestamp":1662203904000},"page":"998-1006","source":"Crossref","is-referenced-by-count":19,"title":["A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA\u00ae (ACT)-Bridge study"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Drug Safety Division, Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amika","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Drug Safety Division, Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-2587","authenticated-orcid":false,"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute , Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"2023082610104418400_R1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/BOR.0000000000000343","article-title":"Takayasu arteritis: an update","volume":"29","author":"Seyahi","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2023082610104418400_R2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.29245\/2572-9411\/2017\/2.1048","article-title":"Takayasu\u2019s arteritis\u2013a comprehensive review","volume":"2","author":"Natraj Setty","year":"2017","journal-title":"J Rare Dis Res Treat"},{"key":"2023082610104418400_R3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14397595.2018.1546358","article-title":"Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy","volume":"29","author":"Yoshifuji","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023082610104418400_R4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.114.012547","article-title":"Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: age and sex specificity","volume":"132","author":"Watanabe","year":"2015","journal-title":"Circulation"},{"key":"2023082610104418400_R5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 Guideline on management of vasculitis syndrome\u2013digest version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ J"},{"key":"2023082610104418400_R6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.08.001","article-title":"Overall survival and mortality risk factors in Takayasu\u2019s arteritis: a multicenter study of 318 patients","volume":"96","author":"Mirouse","year":"2019","journal-title":"J Autoimmun"},{"key":"2023082610104418400_R7","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/01.CIR.90.4.1855","article-title":"Long-term outcome for 120 Japanese patients with Takayasu\u2019s disease. Clinical and statistical analyses of related prognostic factors","volume":"90","author":"Ishikawa","year":"1994","journal-title":"Circulation"},{"key":"2023082610104418400_R8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/ket320","article-title":"Management of Takayasu arteritis: a systematic review","volume":"53","author":"Keser","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104418400_R9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023082610104418400_R10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1536\/ihj.54.405","article-title":"Tocilizumab for the treatment of patients with refractory Takayasu arteritis","volume":"54","author":"Nakaoka","year":"2013","journal-title":"Int Heart J"},{"key":"2023082610104418400_R11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2019.01.010","article-title":"Autophagy promotes aortic adventitial fibrosis via the IL-6\/Jak1 signaling pathway in Takayasu\u2019s arteritis","volume":"99","author":"Chen","year":"2019","journal-title":"J Autoimmun"},{"key":"2023082610104418400_R12","article-title":"European Medicines Agency: RoActemra"},{"key":"2023082610104418400_R13","article-title":"U.S. Food and Drug Administration: ACTEMRA (tocilizumab) injection"},{"key":"2023082610104418400_R14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023082610104418400_R15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023082610104418400_R16","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104418400_R17","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/rheumatology\/keab684","article-title":"Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial","volume":"61","author":"Nakaoka","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104418400_R18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2023082610104418400_R19","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/S0167-5273(96)02813-6","article-title":"Angiographic findings of Takayasu arteritis: new classification","volume":"54","author":"Hata","year":"1996","journal-title":"Int J Cardiol"},{"key":"2023082610104418400_R20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2018.04.002","article-title":"Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients","volume":"91","author":"Mekinian","year":"2018","journal-title":"J Autoimmun"},{"key":"2023082610104418400_R21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","article-title":"Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicenter retrospective study of 209 patients","volume":"61","author":"Mekinian","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104418400_R22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.114.014321","article-title":"Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients","volume":"132","author":"Mekinian","year":"2015","journal-title":"Circulation"},{"key":"2023082610104418400_R23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/1756-185X.12220","article-title":"Rapid control of disease activity by tocilizumab in 10 \u2018difficult-to-treat\u2019 cases of Takayasu arteritis","volume":"16","author":"Goel","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"2023082610104418400_R24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.semarthrit.2020.01.005","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis","volume":"50","author":"Campochiaro","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023082610104418400_R25","first-page":"31","article-title":"Anti-interleukin-6 (tocilizumab) therapy in Takayasu\u2019s arteritis: a real life experience","volume":"50","author":"Kili\u00e7","year":"2020","journal-title":"Turk J Med Sci"},{"key":"2023082610104418400_R26","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s10067-020-05005-7","article-title":"Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis","volume":"39","author":"Pan","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2023082610104418400_R27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jjcc.2020.12.011","article-title":"Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment","volume":"77","author":"Isobe","year":"2021","journal-title":"J Cardiol"},{"key":"2023082610104418400_R28","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02311-y","article-title":"Tocilizumab in treatment-na\u00efve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial","volume":"22","author":"Mekinian","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023082610104418400_R29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s10157-012-0697-0","article-title":"The Asia Pacific meeting on vasculitis and ANCA 2012 workshop on Takayasu arteritis: advances in diagnosis and medical treatment","volume":"17","author":"Isobe","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"2023082610104418400_R30","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.39157","article-title":"Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap","volume":"67","author":"Terao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023082610104418400_R31","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2023082610104418400_R32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac099\/45946203\/roac099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/998\/51269804\/roac099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/998\/51269804\/roac099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T06:11:09Z","timestamp":1693030269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/5\/998\/6691446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,3]]},"published-print":{"date-parts":[[2023,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac099","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2022,9,3]]}}}